Form 4: Bio-Rad Laboratories Executive Acquires Stock Options

Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, acquired stock options on March 3, 2025, according to a Form 4 filing.

Summary

• Jonathan P. DiVincenzo, President & COO of Bio-Rad Laboratories, filed a Form 4.
• The filing reports a transaction on March 3, 2025, where DiVincenzo acquired 4,863 non-qualified stock options with an exercise price of $256.45.
• These options vest over four years, at a rate of 25% per year on the anniversary of the grant date.
• The options expire on March 3, 2035.
• Following the reported transaction, DiVincenzo directly owns 4,863 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard executive compensation disclosure. The acquisition of stock options can be seen as a positive sign, but it's not a major event.

Positives

• The acquisition of stock options by a high-ranking executive can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of executive compensation and provide transparency into the holdings of company insiders. This filing indicates that the executive is incentivized to increase shareholder value.

Stakeholder Impact

• The acquisition of stock options aligns the executive's interests with those of the shareholders.

Key Dates